6190.T
PhoenixBio Co., Ltd.
$460.00
%
Analyst Rating:N/A

Stock Details

CEO

Takashi Shimada

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

70

Address

3-4-1 Kagamiyama, Higashihiroshima, 739-0046

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for PhoenixBio Co., Ltd.  $460.00

EPS

Revenue

Congress Tracker 

Insider Trading of Key Employees

Financial News: 6190.T